Please login to the form below

Not currently logged in
Email:
Password:

Gamida Cell strengthens leadership team

Appoints Josh Hamermesh and Paul Nee

Josh HamermeshCellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh.

Hamermesh (pictured right), who joins from Locust Walk Partners where he served as senior vice president, will lead the business operations and corporate development strategies for the company.

He has also served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities.

Paul NeeAlongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.

Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.

Julian Adams, chairman and chief executive officer of Gamida Cell, said: “We are pleased to welcome Josh and Paul to the Gamida Cell leadership team.

“Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic diseases.”

4th May 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...